Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. We report the case of a 35-year-old woman with severe asthma, who experienced anaphylaxis following the administration of benralizumab, mepolizumab, and omalizumab, separately. The therapy with biologics was chosen to avoid the repeated use of systemic corticosteroids for asthma exacerbations. The mechanisms underlying anaphylaxis caused by these three biologics remain unclear. The patient’s asthma symptoms and lung function improved after treatment with bronchial thermoplasty. To our knowledge, this is the first report of an asthmatic patient developing anaphylaxis after commencement of benralizumab, mepolizumab, and omalizumab therapy. These three biologics should be administered carefully, and patients should be monitored for anaphylaxis.

中文翻译：

---

对三种治疗严重哮喘的人源化抗体的过敏反应：案例研究。


奥马珠单抗、美泊利珠单抗、贝那利珠单抗和杜匹鲁单抗是日本目前用于治疗哮喘的生物制剂。美泊利珠单抗或贝那利珠单抗治疗后出现过敏反应的情况很少见。我们报告了一名患有严重哮喘的 35 岁女性的病例，她在分别服用贝那利珠单抗、美泊利珠单抗和奥马珠单抗后出现过敏反应。选择生物制剂治疗是为了避免重复使用全身性皮质类固醇治疗哮喘加重。这三种生物制剂引起过敏反应的机制尚不清楚。经过支气管热成形术治疗后，患者的哮喘症状和肺功能得到改善。据我们所知，这是首例哮喘患者在开始贝那利珠单抗、美泊利珠单抗和奥马珠单抗治疗后出现过敏反应的报告。这三种生物制剂应谨慎使用，并应监测患者的过敏反应。